Document Detail

Effects of low osmolality contrast materials on coronary hemodynamics, myocardial function, and coronary sinus osmolality in normal and ischemic states.
MedLine Citation:
PMID:  7118517     Owner:  NLM     Status:  MEDLINE    
The effects of intracoronary administration of contrast materials on regional and global left ventricular (LV) function and coronary sinus osmolality were assessed in six anesthetized dogs with segmental myocardial ischemia produced by critical stenosis of the circumflex coronary artery. Effects caused by Renografin (sodium meglumine diatrizoate), two new low osmolality contrast agents (Hexabrix and Hexabrix with added calcium ions), and metrizamide were evaluated. In a nonischemic state, Renografin produced an early (0-10 seconds) decrease in LV contractility followed by a late (10-20 seconds) rebound augmentation in contractility. In the presence of regional ischemia, there are prolongation of the depression of the myocardial contractile state. The monoacid dimer, Hexabrix, demonstrated a similar biphasic response, although the initial depression of myocardial contractility was significantly less than that observed with Renografin. Hexabrix with added calcium ions and metrizamide produced only augmentation in global and regional parameters of LV contractile function. This lack of depressant effects was also observed in the ischemic state. Renografin caused a significantly greater increase in coronary sinus osmolality (Tp) as compared with Hexabrix, Hexabrix-Ca++, and metrizamide. The increases in osmolality in response to the latter three contrast agents were statistically indistinguishable.
A L Deutsch; K H Gerber; F H Haigler; C B Higgins
Related Documents :
10640437 - Nitric oxide effects on myocardial function and force-interval relations: regulation of...
23590907 - Citalopram enhances neurovascular regeneration and sensorimotor functional recovery aft...
10850527 - A mechanistic analysis of reduced mechanical performance in human heart failure.
23667497 - Impact of scotland's comprehensive, smoke-free legislation on stroke.
14579397 - Magnetic resonance imaging of myocardial contrast enhancement with ms-325 and its relat...
20237007 - Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Investigative radiology     Volume:  17     ISSN:  0020-9996     ISO Abbreviation:  Invest Radiol     Publication Date:    1982 May-Jun
Date Detail:
Created Date:  1982-12-02     Completed Date:  1982-12-02     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0045377     Medline TA:  Invest Radiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  284-91     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Contrast Media / administration & dosage*,  pharmacology
Coronary Circulation / drug effects
Coronary Disease / physiopathology*
Coronary Vessels
Diatrizoate / pharmacology
Diatrizoate Meglumine / pharmacology
Drug Combinations / pharmacology
Heart / drug effects*,  physiology,  physiopathology*
Ioxaglic Acid
Metrizamide / pharmacology
Myocardial Contraction / drug effects*
Osmolar Concentration
Triiodobenzoic Acids / pharmacology
Grant Support
Reg. No./Substance:
0/Contrast Media; 0/Drug Combinations; 0/Triiodobenzoic Acids; 117-96-4/Diatrizoate; 131-49-7/Diatrizoate Meglumine; 31112-62-6/Metrizamide; 59017-64-0/Ioxaglic Acid; 8064-12-8/urovision

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Neurotoxic effects of water-soluble contrast agents on rat hippocampus: extracellular recordings.
Next Document:  Comparative effects of ionic anc nonionic contrast materials on coronary and peripheral blood flow.